---
title: "Barinthus Biotherapeutics plc (BRNS.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/BRNS.US.md"
symbol: "BRNS.US"
name: "Barinthus Biotherapeutics plc"
industry: "生物技术"
---

# Barinthus Biotherapeutics plc (BRNS.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [www.barinthusbio.com](https://www.barinthusbio.com) |

## Company Profile

Barinthus Biotherapeutics plc 是一家临床阶段的生物制药公司，专注于开发用于治疗自身免疫和炎症性疾病的免疫治疗药物候选者。其主要候选药物 VTP-1000 目前正在进行 I 期临床试验，旨在恢复患有乳糜泻患者对谷蛋白的免疫非应答。该公司还在开发 VTP-300，一种针对慢性乙型肝炎病毒感染的免疫治疗；VTP-200，一种潜在的非侵入性治疗持久高风险人乳头瘤病毒的药物；VTP-850，一种针对前列腺癌的免疫治疗候选药物；VTP-600，一种针对 MAGE-A3 和 NY-ESO1 抗原的免疫治疗候选药物；VTP-500，一种预防中东呼吸综合症的预防性疫苗候选药物；VT...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-24T04:30:11.000Z

**Overall: D (0.75)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 308 / 404 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -100.00% |  |
| Net Profit YoY | -31.22% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.28 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 23.69M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 0.00 |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -62.26% | E |
| Profit Margin | 0.00% | D |
| Gross Margin | 0.00% | E |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -100.00% | E |
| Net Profit YoY | -31.22% | D |
| Total Assets YoY | -42.13% | E |
| Net Assets YoY | -46.97% | E |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 0.00% | D |
| OCF YoY | -100.00% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 22.56% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Barinthus Biotherapeutics plc",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-62.26%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-100.00%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-31.22%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-42.13%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-46.97%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-100.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "22.56%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制药 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel制药 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.31 | 116/603 | - | - | - |
| PB | 0.28 | 16/603 | 0.47 | 0.35 | 0.30 |
| PS (TTM) | 2.92 | - | 3.29 | 2.92 | 2.51 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-12-11T05:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 2 | 67% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.59 |
| Highest Target | 7.00 |
| Lowest Target | 4.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/BRNS.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/BRNS.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/BRNS.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.